Арилжаа Chugai Pharmaceutical Co., Ltd. - 4519 CFD

Арилжааны нөхцөл

• Төрөл: CFD
• Спред: 21.5
• Лонг позицын шөнийн санхүүжилтийн тохируулга: -0.01305%
• Шорт позицын нэг шөнийн санхүүжилтийн тохируулга: -0.00917%
• Шөнийн санхүүжилтийг тохируулах хугацаа: 22:00 (UTC)
• Валют: JPY
• Арилжаалсан доод хэмжээ: 1
• Маржин: 5.00%
• Хөрөнгийн бирж: Japan
• Арилжааны шимтгэл: 0%
• Баталгаат стопын шимтгэл: 1%

Гол үзүүлэлтүүд

• Өмнөх Хаах: 8421.6
• Нээх: 8268.8
• 1 жилийн өөрчлөлт: 29.25%
• Өдрийн диапазон: 8268.8 - 8409.6

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.